BofA Turns Neutral on Carvana Amid Rising Oil Prices
BofA cut Carvana to Neutral: higher gas and rates hurt buyers, so upside is limited and risks are now evenly balanced.
Already have an account? Sign in.
BofA cut Carvana to Neutral: higher gas and rates hurt buyers, so upside is limited and risks are now evenly balanced.
Roche-Ionis sefaxersen beat placebo on proteinuria at week 37 in IgAN Phase 3. Monthly shot enters crowded market vs Novartis Fabhalta.
Doctors see 35%–40% U.S. share; peak sales estimate raised to about $400 million.
Investors sold CGNX on valuation and cash spend.